Published in Managed Care Law Weekly, December 24th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Critical Therapeutics.
Report 1: Critical Therapeutics, Inc. (CRTX) announced a new business strategy to focus the company's resources on the commercialization of the twice daily, controlled-release formulation of zileuton (zileuton CR) for the chronic treatment of asthma and on clinical development of the intravenous formulation of zileuton (zileuton IV) for acute asthma.
As part of this initiative, Critical Therapeutics will significantly reduce net cash...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly